Metacrine, Inc. (MTCR)
| Market Cap | 88.33M |
| Revenue (ttm) | 2.18M |
| Net Income (ttm) | n/a |
| Shares Out | 26.21M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $3.37 |
| Previous Close | $3.37 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 3.37 |
| Day's Range | 3.30 - 3.47 |
| Day's Volume | 41,802 |
| 52-Week Range | 3.30 - 16.19 |
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...
Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021
Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily ...
SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...
On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...
Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that t...
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...
Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combi...
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...
Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH
New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of Treatment New Data Support Robust, Sustaine...
Did you miss the Metacrine IPO? No worries.
Shares of Metacrine Inc. got a bullish start to their public life, as they opened 10.7% their initial public offering price.
About MTCR
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of ... [Read more...]
| Industry Biotechnology | IPO Date Sep 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol MTCR |
Analyst Forecasts
According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 19.83, which is an increase of 488.43% from the latest price.